Prescribing Dextromethorphan-Bupropion

Why Dextromethorphan-Bupropion Matters

Auvelity is two old drugs in one tablet, and the pairing is mostly about pharmacokinetics. Dextromethorphan, the cough suppressant, is an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist. Taken alone, most people clear it through CYP2D6 with a half-life of about 4 hours. Bupropion inhibits CYP2D6, so in the combination dextromethorphan's half-life roughly triples to about 22 hours, and at steady state it accumulates 20-fold (peak) to 32-fold (AUC), against 1.3- and 1.4-fold when dextromethorphan is given without bupropion. The bupropion also brings its own antidepressant effect at 210 mg/day.

It has two approvals. Major depressive disorder in adults came first (August 2022). On April 30, 2026, the FDA added agitation associated with dementia due to Alzheimer's disease, making it the first approved option for that problem that is not an antipsychotic. Its only boxed warning is the antidepressant suicidality warning; there is no dementia-mortality box.

Its advantage in depression is speed: in the pivotal placebo-controlled trial it separated from placebo at week 1, and in a small trial it beat bupropion alone. The size of the benefit is modest (3.9 MADRS points over placebo at week 6), and the one large trial in treatment-resistant depression missed its primary endpoint. Every patient on it carries bupropion's seizure and blood-pressure risks plus a long list of CYP2D6 and serotonergic interactions. It is brand-only, and the generic settlement with Teva allows no launch before September 30, 2038.

Part 1: Indications

FDA-Approved Uses

• Major depressive disorder (adults)
• Agitation associated with dementia due to Alzheimer's disease (added April 2026). The label limits it: Auvelity is not indicated as an as-needed ("prn") treatment for agitation.

Not approved: bipolar depression (the label says so directly), patients under 18, and treatment-resistant depression as a separate indication.

Off-Label / Emerging

• Bipolar depression: not approved, and Auvelity itself has not been tested there. Small bipolar depression studies of dextromethorphan paired with quinidine found no manic switching, which is not enough to use it in bipolar patients.
• Separate generic dextromethorphan plus bupropion: a cost workaround. It is off-label and untested as a pair; see Part 4.

The Evidence by Indication

MDD, the placebo-controlled trial (GEMINI; Study 1 in the label). Adults 18 to 65 with MDD (baseline MADRS about 33.5) took 45/105 mg once daily for 3 days, then twice daily, for 6 weeks. MADRS fell 15.9 points on the drug and 12.1 on placebo, a difference of 3.9 (95% CI 1.4 to 6.4). The difference was already significant at week 1 and at week 2, both prespecified secondary endpoints. In the published report (Iosifescu et al., J Clin Psychiatry 2022; 327 randomized), remission was 39.5% vs 17.3% and response 54.0% vs 34.0% at week 6. By my arithmetic from those remission rates, that is about one extra remission for every 5 patients treated. The trial was sponsor-run and lasted 6 weeks.

MDD, against bupropion (ASCEND; Study 2 in the label). This was the confirmatory study, and it asked whether the dextromethorphan adds anything. Patients took Auvelity or bupropion SR 105 mg on the same schedule for 6 weeks (Tabuteau et al., Am J Psychiatry 2022). Of 97 randomized, 17 were dropped from the efficacy population because an independent assessor did not confirm the diagnosis or severity, leaving 80. Averaged over weeks 1 to 6, MADRS fell 13.7 points vs 8.8. At week 6 the difference was 5.2 points (CI 1.1 to 9.3), with remission 46.5% vs 16.2%. Response (60.5% vs 40.5%) did not reach significance. Two caveats: the trial was small, and the bupropion arm got 210 mg/day, below the usual 300 mg/day target, so it shows the dextromethorphan contributes without telling you how Auvelity compares with full-dose bupropion.

Treatment-resistant depression (STRIDE-1). In 312 adults who had failed two or three prior treatments, Auvelity was compared with bupropion 150 mg twice daily. At week 6 MADRS fell 11.6 vs 9.4 points (p=0.12), so the primary endpoint failed; week 1 and week 2 secondary endpoints favored Auvelity (Axsome topline release). The full results have not been published.

Long-term, open-label (COMET). 876 patients took 45/105 mg twice daily for up to 12 months. Among the 611 newly enrolled, remission (MADRS 10 or less) was 52.5% at week 6 and 69.0% at month 12, and 8.4% of the full population stopped for adverse events (sponsor poster, ASCP 2021). There was no control group, so read this as evidence of durability and tolerability, not efficacy.

Alzheimer's agitation, acute. The label's acute trial (ADVANCE-1, Study 3) enrolled patients with probable Alzheimer's disease, MMSE 10 to 24, and moderate to severe agitation (median age 75). Over 5 weeks the Cohen-Mansfield Agitation Inventory (CMAI, range 29 to 203) fell 14.9 points on Auvelity and 11.6 on placebo, a difference of 3.3 (CI 0.8 to 5.8). A bupropion-alone arm (49 patients) was stopped early for futility, which is consistent with a contribution from the dextromethorphan. The second acute trial (ADVANCE-2, n=408) missed its primary endpoint: 13.8 vs 12.6 points (p=0.38), per Axsome's December 2024 release.

Alzheimer's agitation, relapse prevention. In ACCORD-2 (Study 4 in the label), responders were randomized to stay on Auvelity or switch to placebo for up to 6 months. Time to relapse was significantly longer on Auvelity, with a hazard ratio of 0.276 and relapse in 8.4% vs 28.6%. The earlier ACCORD-1 withdrawal trial (n=108) also had a hazard ratio of 0.275 (p=0.014). Those figures come from the company's releases and Psychiatric Times; the label shows only the Kaplan-Meier curve.

Who Is a Good Candidate?

• An adult with MDD where a faster start matters, such as a hospitalized patient or anyone else who needs rapid relief
• An older adult with Alzheimer's agitation for whom you want to avoid an antipsychotic
• A patient on few or no CYP2D6-dependent or serotonergic drugs

Who Is a Poor Candidate?

• Anyone with a seizure disorder, a current or past eating disorder, or an abrupt stop of alcohol, benzodiazepines, barbiturates or antiepileptics (all contraindications)
• A patient on an MAOI, or within 14 days of one
• Uncontrolled hypertension (bupropion raises blood pressure)
• Bipolar disorder, or a strong family history of it
• Treatment-resistant depression, where the one large trial failed
• A patient with a history of dextromethorphan or dissociative misuse; see Part 7
• Pregnancy, plans for pregnancy, or breastfeeding (the label says not recommended)
• A patient on several narrow-margin CYP2D6 substrates

Part 2: Mechanism

Neither ingredient's therapeutic mechanism is settled. Dextromethorphan's mechanism in either indication is unclear, and bupropion's antidepressant mechanism is unclear but may relate to noradrenergic or dopaminergic effects. What is established:

• Dextromethorphan: an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist. Auvelity was the first oral antidepressant to act beyond the traditional monoamines, and it shares its glutamate target with ketamine. Dextromethorphan also inhibits serotonin reuptake, which explains its place in the serotonin syndrome warnings.
• Bupropion: a relatively weak inhibitor of norepinephrine and dopamine reuptake. It does not inhibit serotonin reuptake or monoamine oxidase.
• The booster effect: bupropion competitively inhibits CYP2D6, the main route that turns dextromethorphan into dextrorphan. Its three active metabolites (hydroxybupropion, erythrohydroxybupropion and threohydroxybupropion) inhibit CYP2D6 too.

Pharmacokinetics. Each tablet has immediate-release dextromethorphan hydrobromide (30 or 45 mg; 45 mg equals about 33 mg of base) and extended-release bupropion hydrochloride 105 mg. Peak levels come at about 3 hours for dextromethorphan and 2 hours for bupropion. Food lowered dextromethorphan AUC by 14% and barely changed bupropion, so it can be taken either way. Steady state takes about 8 days. Dextromethorphan kinetics are nonlinear in the combination: exposure rises more than proportionally with dose. Half-lives are about 22 hours for dextromethorphan, 15 hours for bupropion, and 33 to 44 hours for the bupropion metabolites. CYP2B6 is the main enzyme forming hydroxybupropion, and a 2B6 inducer cut exposure to both drugs (Part 8). Protein binding is 60% to 70% for dextromethorphan and 84% for bupropion. Dextromethorphan is a P-gp substrate.

Exposure shifts in the label's special-population studies: in moderate renal impairment, dextromethorphan AUC was 2.21 times and bupropion AUC 1.80 times that of matched controls. In known CYP2D6 poor metabolizers, dextromethorphan AUC was 3.40 times higher, with bupropion unchanged. Moderate hepatic impairment and age 65 to 85 changed little. At the maximum dose, Auvelity does not prolong the QT interval to any clinically relevant extent.

Part 3: Before You Start: Workup and Candidacy

Before the first dose, check blood pressure, screen for a personal or family history of bipolar disorder, mania or hypomania, and ask about any other product containing bupropion or dextromethorphan. Those three are label requirements; the rest of this table follows from the contraindications and warnings.

For Alzheimer's agitation, ask the caregiver which behaviors are the target, how often they happen, and whether the patient has falls, gait problems, low sodium, or takes a diuretic. All of these change risk in this age group.

Part 4: How to Start and Dose

Starting in MDD

Dosing follows the trial schedule: one tablet each morning for three days, then one tablet twice daily from day 4. Two tablets a day (90 mg dextromethorphan HBr, 210 mg bupropion HCl) is both the target and the ceiling. There is no labeled step above it, and no lower maintenance dose for patients without a renal, CYP2D6 or poor-metabolizer reason.

Timing

The first dose goes in the morning, and the second at least 8 hours later. Both components are long-lived in the combination, and the 8-hour gap is a label requirement. Tell patients a missed dose is skipped, not made up; the Medication Guide says to wait for the next regular dose.

If the Twice-Daily Dose Is Not Tolerated

No slower MDD schedule is labeled, and efficacy below two tablets a day was not tested in GEMINI. With the separate generic components, one option is to add dextromethorphan at a lower evening dose and raise it toward 45 mg twice daily as tolerated.

Starting in Alzheimer's Agitation

Use the 30/105 mg tablet for the first two weeks: once daily in week 1, twice daily in week 2, then 45/105 mg twice daily from day 15 if tolerated. The bottle of 30/105 mg tablets holds 21, which matches that two-week titration. With moderate renal impairment, a strong CYP2D6 inhibitor or known poor metabolizer status, stay at once daily and step from 30/105 to 45/105 mg on day 8.

Switching and Adding

• From another bupropion product: Auvelity contains bupropion, and seizure risk rises with dose. Screen for other bupropion products first; if both are clinically warranted, the label asks you to tell the patient about the seizure risk. For another dextromethorphan product, it asks you to monitor for neuropsychiatric reactions.
• From or onto an MAOI: 14 days in each direction. Starting Auvelity in a patient getting linezolid or IV methylene blue is contraindicated. If linezolid or IV methylene blue becomes necessary during treatment, stop Auvelity before starting it.
• Adding to an SSRI or TCA: the label warns this combination increases serotonin syndrome risk. If the SSRI is fluoxetine or paroxetine, both strong CYP2D6 inhibitors, the dose limit drops to one tablet a day too. In the first year on the market, 71% of US patients started Auvelity as an add-on, most often to an SSRI (Muzyk et al., J Med Econ 2024, sponsor-funded claims data), so this is a common situation.

The Generic Workaround

The two generic components can stand in for the brand: dextromethorphan at the same 45 mg twice daily, given as 7.5 mL of a 30 mg/5 mL extended-release suspension (about $20 a month in 2023) plus bupropion IR 100 mg twice daily or SR 200 mg a day, against roughly $1,200 a month out of pocket for the brand at that time. The benefit is presumably similar, though no trial has tested the separate components as a pair, and the release profiles differ (Auvelity's dextromethorphan is immediate-release and its bupropion extended-release). A 2026 J Am Geriatr Soc commentary (Brown, Semla and Reuben) raised the same combination-versus-separate-drugs question for dementia agitation. Over-the-counter concentrations vary, so 7.5 mL of a different product is a different dose; write the dose in milligrams and name the product. If you use the components, every warning in this guide still applies.

Part 5: Monitoring

There are no drug levels and no routine labs. Most of the work is blood pressure, mood, and watching for the dose-related effects of each ingredient.

Warn patients and any program that drug-tests them: bupropion can cause false-positive urine immunoassays for amphetamines, even after it is stopped. Confirmatory testing such as GC/MS separates the two.

Part 6: Side Effects and How to Manage Them

In GEMINI, 4% of patients on Auvelity and 0% on placebo stopped for adverse reactions; anxiety (2%) was the only reason at 1% or more. In the 5-week agitation trial, discontinuation was 1.3% in both arms. The rates below are drug vs placebo from the label's tables.

Dizziness

The most common complaint in both programs: 16% vs 6% in GEMINI (14% vs 6% across the depression studies) and 9% vs 3% in the agitation trial. It is a labeled warning because of falls.

• Management: rise slowly, check standing blood pressure if it persists, and caution about driving until the patient knows how the drug affects them. In older adults with gait problems or prior falls, the label asks for fall precautions.

Nausea, Diarrhea, Dyspepsia, Dry Mouth

In GEMINI, nausea was 13% vs 9%, diarrhea 7% vs 3%, dry mouth 6% vs 2% and constipation 4% vs 2%. Decreased appetite was 4% vs 1%. In the agitation trial, dyspepsia (including abdominal discomfort and reflux) was 6% vs 1% and nausea 5% vs 3%.

Headache, Somnolence, Fatigue

Headache was 8% vs 4% and somnolence 7% vs 3% in GEMINI. In the agitation trial, somnolence was 8% vs 4% and fatigue 6% vs 3%.

Anxiety and Insomnia

Anxiety was 4% vs 1% and insomnia 4% vs 2% in GEMINI. These are the activating side of bupropion, and anxiety was the leading reason patients stopped.

Sexual Dysfunction

Sexual dysfunction (abnormal orgasm, erectile dysfunction, decreased libido, anorgasmia) ran 6% vs 0% in GEMINI, enough to make the label's most-common list. The published GEMINI and ASCEND reports nonetheless found no increase in sexual dysfunction. No trial compares its sexual side effects with an SSRI's.

Sweating and Sensory Symptoms

Hyperhidrosis was 5% vs 0%, paresthesia 3% vs 0%, blurred vision 3% vs 0% and arthralgia 3% vs 0% in GEMINI. Postmarketing reports for the combination add tinnitus, tremor and a feeling of being abnormal.

Weight

The GEMINI and ASCEND reports found no weight gain, and decreased appetite was more common on the drug.

Dissociation and Psychotic Symptoms

In the depression trials, the published reports found no psychotomimetic effects and no cases of psychosis, dissociation or serotonin syndrome. In older patients with dementia, the agitation trial found psychotic symptoms (delusions, hallucinations, catatonia) were 3% vs 0% and confusional states 3% vs 1%. Bupropion itself carries a labeled warning for delusions, hallucinations, paranoia and confusion, which sometimes resolve with a lower dose or stopping.

Part 7: Toxicity, Overdose, and Boxed Warnings

Contraindications

• Seizure disorder
• Current or prior bulimia or anorexia nervosa (more seizures were seen with immediate-release bupropion in these patients)
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs
• An MAOI now or within 14 days, in either direction; starting Auvelity during linezolid or IV methylene blue treatment
• Hypersensitivity to bupropion, dextromethorphan or the tablet's components. Anaphylaxis, Stevens-Johnson syndrome and serum sickness-like reactions (arthralgia, myalgia, fever with rash) have been reported with bupropion

Seizure

Bupropion's seizure risk is dose-related. With bupropion SR it was about 0.1% at 300 mg/day (about 1.5 times Auvelity's daily bupropion, by the label's arithmetic) and about 0.4% at 400 mg/day. Other drugs that lower the threshold add to it: other bupropion products, antipsychotics, TCAs, theophylline and systemic corticosteroids, as do diabetes treated with insulin or oral agents, anorectics, and heavy use of alcohol, sedatives or opiates. Stop Auvelity and do not restart it after a seizure.

Blood Pressure

Bupropion can raise blood pressure and cause hypertension, and the risk is higher with MAOIs and other drugs that increase dopaminergic or noradrenergic activity. In a smoking-cessation trial, hypertension occurred in 6.1% on bupropion SR plus a nicotine patch vs 2.5% on bupropion SR alone. There are no controlled trials of bupropion after a recent myocardial infarction or in unstable heart disease.

Other Warnings

• Serotonin syndrome: the dextromethorphan carries it. The risk rises with SSRIs and tricyclics. Stop Auvelity and the other serotonergic drug if symptoms appear.
• Mania or hypomania: screen first; not approved for bipolar depression.
• Psychosis and other neuropsychiatric reactions: from bupropion, and from dextromethorphan in overdose (toxic psychosis, stupor, hyperexcitability). Both are dose-related, which is another reason to find any other bupropion or dextromethorphan product.
• Angle-closure glaucoma: avoid in untreated anatomically narrow angles.
• Hyponatremia (warning updated April 2026): one premarketing case reached 115 mmol/L. Risk is higher in older adults, with diuretics or volume depletion, and with a serotonergic antidepressant, possibly through SIADH. Stop the drug if hyponatremia is symptomatic.
• Embryo-fetal toxicity: see Part 9.

Misuse Potential

Neither ingredient is a controlled substance. Dextromethorphan abuse has been reported, mostly in adolescents. The trials saw no drug-seeking but were not designed to detect it, so watch patients with a history of drug abuse for tolerance, dose increases and drug seeking, as the label asks. Bupropion at 400 mg in experienced drug users produced mild amphetamine-like effects, and seizures and deaths have followed intranasal or injected bupropion.

The trial dose of dextromethorphan (90 mg/day) is below recreational doses of plain dextromethorphan, which produce mild stimulation and euphoria at 100 to 600 mg and dissociative hallucinations above 500 mg. Bupropion, though, keeps far more dextromethorphan in the blood than the same dose would leave on its own, and both ingredients have a history of misuse. Patients with a recent substance use disorder were excluded from the trials.

Overdose

Part 8: Drug Interactions

Auvelity both receives and causes interactions. CYP2D6 inhibitors and CYP2B6 inducers change its levels; its own CYP2D6 block changes the levels of other drugs; and the dextromethorphan adds serotonergic risk.

Part 9: Special Populations

Pregnancy

Auvelity is not recommended in pregnancy, which sets it apart from bupropion alone. The concern is animal data with dextromethorphan plus quinidine: fetal malformations in rabbits, embryo-fetal deaths in rats, and neuronal death in the brains of juvenile rats dosed on postnatal day 7, a stage the label equates with the third trimester through early childhood. The label adds that the separate effect of dextromethorphan at clinical doses is unclear. For bupropion alone, registry and claims data (675 and 1,213 first-trimester exposures) did not show an overall increase in malformations, and findings for specific heart defects are inconsistent.

• What the label asks: if a patient becomes pregnant, stop Auvelity and counsel her about the potential risk; use another treatment for patients planning pregnancy. Weigh that against the relapse risk of untreated depression, which the label also describes.
• Register exposures with the National Pregnancy Registry for Antidepressants (1-866-961-2388).

Lactation

Breastfeeding is not recommended during treatment and for 5 days after the last dose. Bupropion and its metabolites reach milk at about 2% of the maternal weight-adjusted dose, and postmarketing reports describe infant seizures with an unclear relationship. Whether dextromethorphan enters milk is unknown, and the juvenile neurotoxicity finding drives the recommendation.

Elderly

• The agitation program supplies most of the data: 720 patients 65 or older, 352 of them 75 or older, with no overall safety or efficacy differences from younger subjects. Exposure in healthy adults aged 65 to 85 was comparable to younger adults.
• Older adults have more hyponatremia, and in this group dizziness means falls.
• In dementia, watch for confusion and psychotic symptoms (3% each in the agitation trial).
• The MDD trials enrolled adults up to 65.

Renal Impairment

• Moderate (eGFR 30 to 59): one tablet a day maximum (Part 4).
• Severe (eGFR 15 to 29): not studied; not recommended.

Hepatic Impairment

• Mild or moderate (Child-Pugh A or B): no adjustment.
• Severe (C): not studied; not recommended. Severe hepatic impairment is also on the label's list of seizure risk factors.

CYP2D6 Poor Metabolizers

Dextromethorphan AUC was 3.4 times higher in known poor metabolizers, so the maximum is one tablet a day. These patients lean on renal excretion: about 26% of the dextromethorphan dose leaves unchanged in their urine, against under 2% in extensive metabolizers.

Pediatric / Adolescent

Not approved, and safety and effectiveness are not established. The suicidality warning is strongest in this group, and the label notes that dextromethorphan misuse has been reported mostly in adolescents.

Part 10: Discontinuation and Taper

The prescribing information describes no discontinuation syndrome and gives no taper schedule. The Medication Guide, however, warns patients that stopping suddenly may cause serious side effects, so plan any stop with them.

• MDD: there is no randomized withdrawal trial, so the evidence does not say how long to continue. Reasoning from other augmentation research, a sensible plan is to wait for at least six months of recovery before tapering the dextromethorphan, taper it over at least one to two months, and raise bupropion to the usual 300 mg/day if the patient stays on bupropion.
• Alzheimer's agitation: the withdrawal trial is the best evidence. In ACCORD-2, agitation relapsed in 28.6% switched to placebo vs 8.4% who stayed on the drug. Reassess the need periodically, but expect symptoms to return in some patients.
• After stopping: wait 14 days before an MAOI and 5 days before breastfeeding. Bupropion's CYP2D6 inhibition outlasts the last dose: in the Wellbutrin XL label, the desipramine effect was still present at least 7 days after bupropion stopped. Expect 2D6 substrates you lowered to fall back over that week or longer, and reassess their doses.
• After a seizure: stop and do not restart.

Part 11: Dextromethorphan-Bupropion vs the Alternatives

No head-to-head trial compares Auvelity with an SSRI, an SNRI, or an antipsychotic augmentation strategy in depression. The comparisons below are only the ones the sources support.

The Bedside Cheat Sheet